AstraZeneca PLC's ARCTIC study of its PD-L1 inhibitor/CTLA4 combination of Infimzi (durvalumab) and tremelimumab has failed to produce either a progression-free or survival benefit when used in the late-stage treatment of advanced non-small cell lung cancer (NSCLC) patients, initial data show.
The result was not unexpected following the initial disappointing PFS data for the combination from MYSTIC in first-line metastatic NSCLC...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?